1009 related articles for article (PubMed ID: 30189190)
21. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
22. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
Hu X; Ren J; Xue Q; Luan R; Ding D; Tan J; Su X; Yang J
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37681488
[TBL] [Abstract][Full Text] [Related]
23. Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer.
Shroff GS; Strange CD; Ahuja J; Altan M; Sheshadri A; Unlu E; Truong MT; Vlahos I
Radiographics; 2022; 42(7):1956-1974. PubMed ID: 36240075
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.
Chao Y; Zhou J; Hsu S; Ding N; Li J; Zhang Y; Xu X; Tang X; Wei T; Zhu Z; Chu Q; Neal JW; Wu JT; Song Y; Hu J
Transl Lung Cancer Res; 2022 Feb; 11(2):295-306. PubMed ID: 35280322
[TBL] [Abstract][Full Text] [Related]
25. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
[TBL] [Abstract][Full Text] [Related]
26. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
[TBL] [Abstract][Full Text] [Related]
27. Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients.
Araki T; Kanda S; Ide T; Sonehara K; Komatsu M; Tateishi K; Minagawa T; Kiniwa Y; Kawakami S; Nomura S; Okuyama R; Hanaoka M; Koizumi T
ESMO Open; 2023 Dec; 8(6):102030. PubMed ID: 37852033
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Tan PS; Aguiar P; Haaland B; Lopes G
Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
[TBL] [Abstract][Full Text] [Related]
29. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.
Sears CR; Peikert T; Possick JD; Naidoo J; Nishino M; Patel SP; Camus P; Gaga M; Garon EB; Gould MK; Limper AH; Montgrain PR; Travis WD; Rivera MP
Am J Respir Crit Care Med; 2019 Sep; 200(6):e31-e43. PubMed ID: 31518182
[No Abstract] [Full Text] [Related]
30. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
[TBL] [Abstract][Full Text] [Related]
31. Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature.
L Gemmill JA; Sher A
Cancer Invest; 2020 Jul; 38(6):365-371. PubMed ID: 32559143
[TBL] [Abstract][Full Text] [Related]
32. Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis.
El-Osta H; Jafri S
Immunotherapy; 2019 Feb; 11(3):189-199. PubMed ID: 30730276
[TBL] [Abstract][Full Text] [Related]
33. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary toxicity of systemic lung cancer therapy.
Long K; Suresh K
Respirology; 2020 Nov; 25 Suppl 2():72-79. PubMed ID: 32729207
[TBL] [Abstract][Full Text] [Related]
35. Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report.
Miao K; Xu Y; Xu W; Zhang Y; Xu Y; Tian X; Zhang L
Thorac Cancer; 2021 Aug; 12(15):2214-2216. PubMed ID: 34145962
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Pang L; Xie M; Ma X; Huang A; Song J; Yao J; Deng H; Zhang D; Zang X; Ren F; Gao J; Wu C; Wang Y; Zhang X; Bao X; Pan L; Xue X
BMC Cancer; 2023 Mar; 23(1):203. PubMed ID: 36869304
[TBL] [Abstract][Full Text] [Related]
37. [A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].
Liu Y; Zhang T; Gao Y; Qu Y; Lu B; Zhang H; Wang Q; Li J; Hu F; Li B
Zhongguo Fei Ai Za Zhi; 2019 Nov; 22(11):687-695. PubMed ID: 31771737
[TBL] [Abstract][Full Text] [Related]
38. Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer.
Zaim R; Redekop K; Uyl-de Groot CA
J Cancer Policy; 2023 Mar; 35():100382. PubMed ID: 36592861
[TBL] [Abstract][Full Text] [Related]
39. Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges.
O'Leary CL; Pierce N; Patel SP; Naidoo J
J Thorac Oncol; 2024 Mar; 19(3):395-408. PubMed ID: 38012985
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician.
Hansen ED; Wang X; Case AA; Puzanov I; Smith T
J Pain Symptom Manage; 2018 Sep; 56(3):460-472. PubMed ID: 29792979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
